Guida Maurizio, Terracciano Daniela, Cennamo Michele, Aiello Federica, La Civita Evelina, Esposito Gennaro, Gargiulo Valentina, Maruotti Giuseppe M, Portella Giuseppe, Sarno Laura
Department of Neurosciences, Reproductive Science and Dentistry, University of Naples "Federico II", 80131 Naples, Italy.
Department of Translational Medical Sciences, University of Naples "Federico II", 80131 Naples, Italy.
Vaccines (Basel). 2021 Jul 13;9(7):785. doi: 10.3390/vaccines9070785.
The objective of this research is to demonstrate the release of SARS-CoV-2 Spike (S) antibodies in human milk samples obtained by patients who have been vaccinated with mRNABNT162b2 vaccine.
Milk and serum samples were collected in 10 volunteers 20 days after the first dose and 7 seven days after the second dose of the mRNABNT162b2 vaccine. Anti-SARS-CoV-2 S antibodies were measured by the Elecsys Anti-SARS-CoV-2 S ECLIA assay (Roche Diagnostics AG, Rotkreuz, Switzerland), a quantitative electrochemiluminescence immunometric method.
At first sample, anti-SARS-CoV-2 S antibodies were detected in all serum samples (103.9 ± 54.9 U/mL) and only in two (40%) milk samples with a low concentration (1.2 ± 0.3 U/mL). At the second sample, collected 7 days after the second dose, anti-SARS-CoV-2 S antibodies were detected in all serum samples (3875.7 ± 3504.6 UI/mL) and in all milk samples (41.5 ± 47.5 UI/mL). No correlation was found between the level of serum and milk antibodies; the milk antibodies/serum antibodies ratio was on average 2% (range: 0.2-8.4%).
We demonstrated a release of anti-SARS-CoV-2 S antibodies in the breast milk of women vaccinated with mRNABNT162b2. Vaccinating breastfeeding women could be a strategy to protect their infants from COVID-19 infection.
本研究的目的是证明接种mRNA BNT162b2疫苗的患者所提供的母乳样本中存在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突（S）抗体。
在10名志愿者中，于接种第一剂mRNA BNT162b2疫苗后20天以及接种第二剂后7天采集乳汁和血清样本。采用电化学发光免疫分析法（ECLIA）（罗氏诊断公司，瑞士罗特kreuz）检测抗SARS-CoV-2 S抗体，这是一种定量电化学发光免疫测定方法。
在首次采样时，所有血清样本中均检测到抗SARS-CoV-2 S抗体（103.9±54.9 U/mL），而仅在两份（40%）乳汁样本中检测到低浓度（1.2±0.3 U/mL）的抗体。在接种第二剂疫苗7天后采集的第二次样本中，所有血清样本（3875.7±3504.6 UI/mL）和所有乳汁样本（41.5±47.5 UI/mL）中均检测到抗SARS-CoV-2 S抗体。血清和乳汁抗体水平之间未发现相关性；乳汁抗体/血清抗体比值平均为2%（范围：0.2 - 8.4%）。
我们证明了接种mRNA BNT162b2疫苗的女性母乳中存在抗SARS-CoV-2 S抗体。为哺乳期妇女接种疫苗可能是保护其婴儿免受2019冠状病毒病感染的一种策略。
